Pathogenesis of HIV: Non-specific immune hyperactivity and its implications for vaccines

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 8, Issue 3, 2008, Pages 267-271

  Cadogan, Martin ^a   Dalgleish, Angus G ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

AIDS; Autoimmunity; Graft versus host disease; HIV; HLA; Immune activation; Immune evasion; Long term non progressors

Indexed keywords

HLA DR ANTIGEN; LEUKOCYTE ANTIGEN;

ANTIGEN PRESENTING CELL; AUTOIMMUNITY; CD4 LYMPHOCYTE COUNT; DISEASE PREDISPOSITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; PATHOGENESIS; REVIEW; T LYMPHOCYTE ACTIVATION; VACCINATION; VIRUS LOAD;

EID: 46949095071     PISSN: 14702118     EISSN: None     Source Type: Journal    
DOI: 10.7861/clinmedicine.8-3-267     Document Type: Review

References (35)

1. Dalgleish AG. The pathogenesis of AIDS: classical and alternative views. J R Coll Physicians Lond 1992;26:152-8.
2. Hazenberg MD, Otto SA, Van Benthem BHB et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003;17:1881-8.
3. Fernandez S, Price P, McKinnon EJ, Nolan RC, French MA. Low CD4+ T-cell counts in HIV patients receiving effective antiretroviral therapy are associated with CD4+ T-cell activation and senescence but not with lower effector memory T-cell function. Clin Immunol 2006;120:163-70.
4. Resino S, Seoane E, Gutierrez MD, Leon JA, Munoz-Fernandez MA. CD4 (+) T-cell immunodeficiency is more dependent on immune activation than viral load in HIV-infected children on highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2006;42:269-76.
5. Poignard P, Sabbe R, Picchio GR et al. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity 1999;10:431-8.
6. Esser MT, Bess JW, Suryanarayana K et al. Partial activation and induction of apoptosis in CD4+ and CD8+ T lymphocytes by conformationally authentic non-infectious human immunodeficiency virus type 1. J Virol 2001;75:1152-64.
7. Liegler TJ, Yonemoto W, Elbeik T et al. Diminished spontaneous apoptosis in lymphocytes from immunodeficiency virus-infected long-term nonprogressors. J Infect Dis 1998;178:669-79.
8. Lawn SD, Butera S, Folks TM. Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection. Clin Microbiol Rev 2001;14:753-77.
9. Musey LK, Krieger JN, Hughes JP et al. Early and persistent human immunodeficiency virus type 1 (HIV-1)-specific T helper dysfunction in blood and lymph nodes following acute HIV-1 infection. J Infect Dis 1999;180:278-84.
10. Giorgi JV, Hultin LE, McKeating JA et al. Shorter survival in advanced human immunodeficiency virus type 1 is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999;179:859-70.
11. Goldstein S, Ourmanov I, Brown CR et al. Wide range of viral load in healthy African green monkeys naturally infected with simian immunodeficiency virus. J Virol 2000;74:11744-53.
12. Tesselaar K, Arens R, Van Schijndel GMW et al. Lethal T cell immunodeficiency induced by chronic costimulation via CD27-CD70 interactions. Nature Immunol 2003;4:49-54.
13. Brenchley JM, Price DA, Douek DC. HIV disease: fallout from a mucosal catastrophe? Nat Immunol 2006;7:235-9.
14. Westby M, Manca F, Dalgleish AG. The role of the immune responses in determining the outcome of HIV infection. Immunol Today 1996;17:120-6.
15. Westby M, Vaughan AN, Balotta C et al. Low CD4 counts rather than superantigenic-like effects account for different expressed T-cell receptor (TCR) repertoires between HIV-1 seropositive long-term non-progressors and individuals with progressive disease. Br J Haematol 1998;102:1187-96.
16. Clapham PR, McKnight A. Cell surface receptors, virus entry and tropism of primate lentiviruses. J Gen Virol 2001;83:1809-29.
17. Susal C, Kropelin M, Daniel V, Opelz G. Molecular mimicry between HIV-1 and antigen receptor molecules: A clue to the pathogenesis of AIDS. Vox Sanguinis 1993;65:10-7.
18. Wucherpfennig KW, Strominger JL. Molecular mimicry in T cell-mediated autoimmunity: Viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995;80:695-705.
19. Sharon M, Kessler N, Levy R et al. Alternative conformations of HIV-1 V3 loops mimic ,-hairpins in chemokines, suggesting a mechanism for coreceptor selectivity. Structure 2003;11:225-36.
20. Kaslow RA, Carrington M, Apple R et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996;2:405-11.
21. Shearer GM. Allogeneic leukocytes as a possible factor in induction of aids in homosexual men. N Engl J Med 1983;308:223-4.
22. Clerici M, Shearer G, Hounsell EF et al. Alloactivated cytotoxic T cells recognize the carboxy terminal domain of human immunodeficiency virus-1 gp120 envelope glycoprotein. Eur J Immunol 1993;23:2022-5.
23. Atassi H, Atassi MZ. HIV envelope protein is recognized as an alloantigen by human DR-specific alloreactive T cells. Hum Immunol 1992;34:31-8.
24. Pugliese O, Viora M, Camponeschi B et al. A gp120 HIV peptide with high similarity to HLA class II β-chains enhances PPD-specific and autoreactive T cell activation. Clin Exp Immunol 1992;90:170-4.
25. Wilson SE, Habeshaw JA, Addawe MA, Hounsell EF, Oxford JS. HIV type 1 envelope glycoprotein 120 carboxy-terminal peptide-induced human T cell lines selectively suppress heterogenous proliferative T cell responses to soluble antigens. AIDS Res Hum Ret 1997;13:1313-24.
26. Hounsell EF, Renouf DV, Liney D, Dalgelish AG, Habeshaw JA. A proposed molecular model for the carboxy terminus of HIV-1 gp120 showing structural features consistent with the presence of a T-cell alloepitope. Mol Aspects of Med 1991;12:283-96.
27. Sheikh J, Ongradi J, Austen B, Dalgleish AG. The gp120 envelope of HIV-1 binds peptides in a similar manner to human leukocyte antigens. AIDS 1995;9:1229-35.
28. Sheikh J, Souberbielle B, Westby M, Austen B, Dalgleish AG. HIV gp120 plus specific peptides are recognized in a similar way to specific HLA plus peptide by HLA restricted antigen specific cell lines. Viral Immunol 2000;13:9-17.
29. Cadogan M, Austen B, Heeney JL, Dalgleish AG. HLA homology within the C5 domain promotes peptide binding by HIV-1 gp120. AIDS Res Hum Retroviruses 2008 (in press).
30. Nag B, Wada HG, Deshpande SV et al. Stimulation of T cells by antigenic peptide complexed with isolated chains of major histocompatibility complex class II molecules. Proc Natl Acad Sci USA 1996;90:1604-8.
31. Loomis-Price LD, Cox JH, Mascola JR et al. Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infection. J Infect Dis 1998;178:1306-16.
32. Brown L, Souberbielle BE, Marriott JB et al. The conserved carboxy terminal region of HIV-1 gp120 is recognised by seronegative HIV-exposed people. AIDS 1999;13:2515-21.
33. Holl V, Peressin M, decoville T et al. Non-neutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. J Virol 2006;80:6177-81.
34. Aasa-Chapman MM, Hayman A, Newton P et al. Development of the antibody response in acute HIV-1 infection. AIDS 2004;18:371-81.
35. Kran AM, Sorensen B, Sommerfeit MA et al. Long-term HIV-specific responses and delayed resumption of antiretroviral therapy after peptide immunization targeting dendritic cells. AIDS 2006;20:627-30.